Genmab — November 2018
-
but at the moment "BCMA in the spotlight as ASH abstracts drop" http://www.pmlive.com/pharma_news/bcma_in_the_spotlight_as_ash_abstracts_drop_1258442 , so as Sukkeralf said, a bit disappointing JNJ has nothing at ASH on the BCMA CD3
-
34 studies of RA enrolling by invitation. https://www.clinicaltrials.gov/ct2/results?recrs=f&cond=Rheumatoid+Arthritis
-
-
skal Isatuximab ikke lige godkendes først i første og anden linje,inden du starter med at bekymre dig om, at de nedsætter prisen?? Er enig med dig i, at SC er sidste forhindring på den vej til +10 B USD Sales
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind